205 related articles for article (PubMed ID: 12200371)
1. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
Blood; 2002 Sep; 100(6):2087-93. PubMed ID: 12200371
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.
Hansen RJ; Balthasar JP
J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia.
Jin F; Tayab ZR; Balthasar JP
AAPS J; 2006 Jan; 7(4):E895-902. PubMed ID: 16594642
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.
Hansen RJ; Balthasar JP
Thromb Haemost; 2002 Dec; 88(6):898-9. PubMed ID: 12529736
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous immunoglobulin on inhibition of fibrinogen binding to platelets by sera from patients with immune thrombocytopenia.
Kamiyama M; Yoshimura Y; Chen K; Arkel YS
Am J Hematol; 1993 Oct; 44(2):77-84. PubMed ID: 8266923
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura.
Hansen RJ; Balthasar JP
J Pharmacol Exp Ther; 2001 Jul; 298(1):165-71. PubMed ID: 11408538
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia.
Deng R; Balthasar JP
J Pharm Sci; 2007 Jun; 96(6):1625-37. PubMed ID: 17238194
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia.
Teeling JL; Jansen-Hendriks T; Kuijpers TW; de Haas M; van de Winkel JG; Hack CE; Bleeker WK
Blood; 2001 Aug; 98(4):1095-9. PubMed ID: 11493456
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG.
Liang SX; Pinkevych M; Khachigian LM; Parish CR; Davenport MP; Chong BH
Blood; 2010 Sep; 116(11):1958-60. PubMed ID: 20566900
[TBL] [Abstract][Full Text] [Related]
10. Generation of two high affinity anti-mouse FcRn antibodies: Inhibition of IgG recycling in wild type mice and effect in a mouse model of immune thrombocytopenia.
Smith B; Christodoulou L; Clargo A; Eddleston A; Greenslade K; Lightwood D; Shock A; Tyson K; Brennan FR
Int Immunopharmacol; 2019 Jan; 66():362-365. PubMed ID: 30529500
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.
Song S; Crow AR; Freedman J; Lazarus AH
Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021
[TBL] [Abstract][Full Text] [Related]
12. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies.
Webster ML; Sayeh E; Crow M; Chen P; Nieswandt B; Freedman J; Ni H
Blood; 2006 Aug; 108(3):943-6. PubMed ID: 16861348
[TBL] [Abstract][Full Text] [Related]
13. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.
Crow AR; Yu H; Han D; Lazarus AH
PLoS One; 2013; 8(8):e71882. PubMed ID: 23940791
[TBL] [Abstract][Full Text] [Related]
15. Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin.
Winkler J; Kroiss S; Rand ML; Azzouzi I; Annie Bang KW; Speer O; Schmugge M
Br J Haematol; 2012 Feb; 156(4):508-15. PubMed ID: 22171764
[TBL] [Abstract][Full Text] [Related]
16. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia.
Crow AR; Suppa SJ; Chen X; Mott PJ; Lazarus AH
Blood; 2011 Dec; 118(24):6403-6. PubMed ID: 22001393
[TBL] [Abstract][Full Text] [Related]
17. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity.
Crow AR; Song S; Semple JW; Freedman J; Lazarus AH
Br J Haematol; 2001 Dec; 115(3):679-86. PubMed ID: 11736954
[TBL] [Abstract][Full Text] [Related]
18. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review.
Warkentin TE
Expert Rev Hematol; 2019 Aug; 12(8):685-698. PubMed ID: 31274032
[No Abstract] [Full Text] [Related]
19. Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia.
Li J; van der Wal DE; Zhu L; Vadasz B; Simpson EK; Li C; Webster ML; Zhu G; Lang S; Chen P; Zeng Q; Ni H
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):50-8. PubMed ID: 23082940
[TBL] [Abstract][Full Text] [Related]
20. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases.
Zhou Z; Qiao Z; Li H; Luo N; Zhang X; Xue F; Yang R
Autoimmunity; 2016; 49(1):50-7. PubMed ID: 26525513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
